Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting

Diseases of the Esophagus

Volumn 19, Issue 6, 2006, Pages 473-476

  Osaka, Y ^a,b   Takagi, Y ^a   Hoshino, S ^a   Tachibana, S ^a   Tsuchida, A ^a   Aoki, T ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Chemotherapy; Docetaxel; Nedaplatin; Outpatient setting; Recurrent esophageal cancer

Indexed keywords

DOCETAXEL; NEDAPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG FATALITY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEASIBILITY STUDY; FEMALE; HUMAN; KIDNEY FAILURE; LEUKOPENIA; MALE; NAUSEA AND VOMITING; OUTPATIENT CARE; PRIORITY JOURNAL; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; TAXOIDS;

EID: 33750464061     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2006.00614.x     Document Type: Article

References (19)

1. Sobin L H, Wittekind C, eds. International Union Against Cancer(UICC) TNM Classification of Malignant Tumors, 5th edn. New York: Wiley-Liss, Inc 1997.
2. Therasse P, Arbuck S G, Eisenhauer E A et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000; 92: 205-16.
3. National Cancer Institute. Common Toxicity Criteria (CTC) version 2.0. Available at: http://ctep.cancer.gov/forms/CTCv20_4-3-992.pdf (Accessed 7 December, 2004).
4. Jones S E, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542-51.
5. Fossella F V, DeVore R, Kerr R N et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354-62.
6. Metges J, Hennequin C, Yehou M et al. Docetaxel as a second-line chemotherapy in metastatic esophageal cancer: A French study. Proc Am Soc Clin Oncol 2001; 20: A635.
7. Muro K, Hamaguchi T, Ohtsu A et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004; 15: 955-9.
8. Vasey S A, Jayson G C, Gordon A et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as firstline chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682-91.
9. Sasaki Y, Shinkai T, Eguchi K et al. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodunamics as determined by bio assay. Cancer Chemother Pharmacol 1991; 27: 263-70.
10. Tsukuda M, Yoshida T, Kubota A et al. Experimental study on the anti-tumor effects of CDDP derivatives against the head and neck squamous cell carcinoma cell lines. Jpn J Cancer Chemother 1988; 15: 2811-14.
11. Alberts D S, Fanta P T, Ruuing K L et al. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancer. Cancer Chemother Pharmacol 1997; 39: 493-7.
12. Kawai Y, Taniuchi S, Okahara S, Nakumura Y, Gemba M. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull 2005; 28: 1385-8.
13. Taguchi T, Wakui A, Nabeya K et al. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Group. Jpn J Cancer Chemother 1992; 19: 483-8.
14. Muro K, Ando N, Nishimaki A. A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) trial (JCOG9905). Proc ASCO 2003; 22: 1112.
15. Yamada H, Uchida N, Maekawa R, Yoshioka T. Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel. Cancer Lett 2001; 22: 17-25.
16. Saito J, Sugawara S, Nakai Y et al. Phase I/II study of combination chemotherapy with docetaxel and nedaplatin for unresectable non-small-cell lung cancer. Jap J Lung Cancer 2000; 40: 513 (in Japanese).
17. Polee M B, Eskens F A, van der Burg M E et al. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 2002; 86: 669-73.
18. Ilson D H, Saltz L, Enzinger P et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17: 3270-5.
19. Shisher S G, Wynn P, Putnam JB et al. Salvage Esophagectomy for reccurent tumors after definitive chemotherpy and radiotherapy. J Thorac Cardiovasc Surg 2002; 123: 175-83.